The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings - CNBC
- The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings CNBC
- Lilly climbs, Novo falls as obesity drug battle intensifies BioPharma Dive
- How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy? MarketWatch
- Lilly confident in slow and steady Foundayo launch, as ex-US sales shine BioSpace
- Lilly’s obesity pill Foundayo ‘disappointed’ in Q2, as injectables continue to boom Fierce Pharma
Related Markets
All MarketsMarket data may be delayed. Not financial advice.
💡 AI analysis provides alternative perspectives on current events